$1.16
-0.08[-6.45%]
At close: May 10
$1.16
0[0.00%]
After Hours: 7:24PM EDT
Oncolytics Biotech
(NASDAQ:ONCY)Latest News for Oncolytics Biotech Stock (NASDAQ:ONCY)
Oncolytics Biotech Stock (NASDAQ: ONCY)
Categories: All
Thursday, May 09, 2024
- Oncolytics Biotech Q1 EPS $(0.07) Beats $(0.08) EstimateBenzinga Newsdesk - 2 days ago
- Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- An Anti-PD-L1 Inhibitor in Pancreatic Cancer, First Patient Expected To Be Enrolled In Q2 2024Benzinga Newsdesk - 2 days ago
Thursday, April 25, 2024
Thursday, April 11, 2024
- Oncolytics Biotech Has Submitted Type C Meeting Request To FDA For Q2 2024 To Discuss The Company's Planned Registration-enabling Trial For Pelareorep In HR+/HER2- Metastatic Breast CancerBenzinga Newsdesk - Apr 11, 2024, 7:20AM
- Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDABenzinga Newsdesk - Apr 11, 2024, 7:05AM
Thursday, April 04, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Wednesday, February 14, 2024
Friday, January 19, 2024
Thursday, January 04, 2024
- HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price TargetBenzinga Newsdesk - Jan 4, 2024, 10:26AM
- Oncolytics Biotech Says It Expects To Initiate First Phase 3 Study For Pelareorep In Pancreatic Cancer This Year, Company Will Provide Guidance On Registration Path For Metastatic Breast Cancer In First Half Of 2024Benzinga Newsdesk - Jan 4, 2024, 7:08AM
Thursday, December 07, 2023
Monday, November 13, 2023
Thursday, November 09, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
Monday, October 23, 2023
Tuesday, September 26, 2023
- The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5M Therapeutic Accelerator Award To Develop Leading-Edge TreatmentsBenzinga Newsdesk - Sep 26, 2023, 8:01AM
- Oncolytics Biotech Bags $5M Therapeutic Accelerator Award From The Pancreatic Action NetworkBenzinga Newsdesk - Sep 26, 2023, 7:04AM
Wednesday, August 16, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
- CORRECTION: Oncolytics Biotech Q2 EPS $(0.09), Inline; Cash, Cash Equivalents Of $24.4MBenzinga Newsdesk - Aug 14, 2023, 7:14AM
- Oncolytics Biotech Q2 EPS $(0.09), Inline; Cash, Cash Equivalents Of $24.4MBenzinga Newsdesk - Aug 14, 2023, 7:05AM
- Earnings Scheduled For August 14, 2023Benzinga Insights - Aug 14, 2023, 6:45AM
Friday, August 11, 2023
Tuesday, August 08, 2023
Monday, July 31, 2023
- Oncolytis Biotech shares are trading lower after the company announced that it entered into an agreement with Leede Jones Gable as an underwriter and bookrunner to purchase, on a brought-deal basis, 6.667 million units for gross proceeds of $15 million at $2.25 per unit.Benzinga Newsdesk - Jul 31, 2023, 12:27PM
- Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/UnitBenzinga Newsdesk - Jul 31, 2023, 6:58AM
Thursday, June 29, 2023
Friday, June 23, 2023
Thursday, June 22, 2023
Wednesday, June 14, 2023
Wednesday, June 07, 2023
Monday, June 05, 2023
Friday, May 26, 2023
Thursday, May 25, 2023
Wednesday, May 24, 2023
- Oncolytics Biotech shares are trading higher after JonesTrading initiated covered on the stock with a Buy rating and announced a $9 price target.Benzinga Newsdesk - May 24, 2023, 12:40PM
- Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023Benzinga Insights - May 24, 2023, 11:00AM
- JonesTrading Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $9Benzinga Newsdesk - May 24, 2023, 4:46AM